Alpha 1 Antitrypsin Deficiency Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026
The global alpha 1 antitrypsin deficiency treatment market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 9.2% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Alpha-1 antitrypsin (AAT) deficiency refers to a genetic disorder due to which the body does not produce sufficient AAT protein. AAT protein is essential for protecting the lungs and liver from the adverse effects of other proteins in the body. Patients with severe AAT deficiency may develop liver cirrhosis, chronic obstructive pulmonary diseases (COPD) and emphysema diseases. It can be diagnosed through a genetic or a blood test. Some of the treatment methods include augmentation therapy, pulmonary rehabilitation and oxygen therapy that use medicines, such as bronchodilators and corticosteroids, which can be injected intravenously or inhaled.
The increasing prevalence of respiratory disorders is one of the key factors driving the growth of the market. Furthermore, widespread adoption of augmentation therapy is providing a thrust to the market growth. This therapy involves extracting AAT protein from a healthy donor’s blood plasma for increasing AAT levels in the respiratory tract of patients. In line with this, this treatment also delays the progression of emphysema, minimizes the frequency of exacerbations and improves recovery speed, which, in turn, is contributing to its increasing preference among both the patients and healthcare providers. Additionally, various technological advancements in the diagnostic methods and the development of innovative processes for the production and purification of AAT are acting as other growth-inducing factors. They have improved quality and are free from contaminants, such as viruses and bacteria. Other factors, including extensive research and development (R&D) activities, along with improvements in medical infrastructure, are anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global alpha 1 antitrypsin deficiency treatment market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, treatment type, route of administration and end user.
Breakup by Treatment Type:
Breakup by Route of Administration:
Breakup by End User:
Breakup by Region:
Middle East and Africa
The competitive landscape of the industry has also been examined with some of the key players being AstraZeneca PLC, Boehringer Ingelheim GmbH, CSL Limited, GlaxoSmithKline Plc, Grifols S.A., Kamada Ltd., LFB Biomedicaments, Pfizer Inc., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd. Key Questions Answered in This Report:
How has the global alpha 1 antitrypsin deficiency treatment market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global alpha 1 antitrypsin deficiency treatment market?
What are the key regional markets?
What is the breakup of the market based on the treatment type?
What is the breakup of the market based on the route of administration?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global alpha 1 antitrypsin deficiency treatment market and who are the key players?
What is the degree of competition in the industry?
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook